Depressive Disorder, MajorNCT05988333
Psychoeducational Intervention for Families With a Member Affected by Major Depression
A study testing Psychoeducational Family Intervention and Informative intervention in people with Depressive Disorder, Major, run by University of Campania Luigi Vanvitelli at 1 site in Italy.
Trial summary
Major depressive disorder (MDD) is the most common mental disorder. It can be a huge burden not only for the person affected by it, but also for his/her whole family. The goal of this clinical trial is to test the efficacy of a family supportive intervention called psychoeducational family intervention (PFI) compared… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Depressive Disorder, Major
- What is being tested?
- Psychoeducational Family Intervention and Informative intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 384 participants
- Where
- 1 siteItaly
- Study dates
- 27 Sep 2023to Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- diagnosis of major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition;
- ability to provide informed consent;
- presence of at least one contact per month with the psychiatric clinic for at least six months prior to recruitment;
- cohabitation with at least one family member.
Who cannot join
- moderate or severe cognitive deficits, physical illnesses preventing the participation to the sessions or if they were hospitalization in the two months prior the enrollment
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
University of Campania L. Vanvitelli
Naples, 80138
Mario Luciano, Doctor
About this study
Official title: The Efficacy of Psychoeducational Family Intervention for Individuals With Major Depression: a Randomized Controlled Trial
Major depressive disorder (MDD) is the most common mental disorder. It can be a huge burden not only for the person affected by it, but also for his/her whole family. The goal of this clinical trial is to test the efficacy of a family supportive intervention called psychoeducational family intervention (PFI) compared to a brief informative intervention in families with a member affected by MDD. Families will participate in one of the two interventions for a period of 6 months more or less, and they will be asked to answer some questionnaires about how much MDD impacts on their everyday life and the patient's symptoms, in order to understand whether a more structured intervention such as PFI can be useful for families in order to better deal with this complicated illness.
Read the detailed description
The present paper is a no-profit, not-funded, national, multicentric, randomized-controlled trial with blinded outcome assessments, carried out in 24 Italian University outpatient units and coordinated by the Department of Mental and Physical Health and Preventive Medicine of the University of Campania Luigi Vanvitelli. In each center, 8 patients (and their families) and 8 controls will be recruited, for a total of 192 families assigned to the experimental group and 192 to the control group (total sample size = 384 families). Families are assessed at the baseline and 6-, 12- and 24-months post-randomization.
The primary aim of this study is to assess the efficacy of PFI in a group of patients with a diagnosis of MDD in terms of: 1) reduction of depressive symptoms; 2) improvement of psychosocial functioning; 3) improvement of social network. Furthermore, the efficacy of PFI will be also evaluated in terms of: 1) reduction of relapses and hospitalization in the 18 months following the end of the intervention; 2) improvement of adherence to pharmacological treatments and of patients' quality of life; 3) reduction of self-stigma; 4) improvement of coping strategies, family burden, and expressed emotion of family members of patients with major depression; 5) improvement of quality of life of family members. Finally, our study will investigate whether the presence of specific temperamental profiles and childhood traumas may mediate the effectiveness of the psychoeducational intervention.
The experimental intervention consists of the psychoeducational family intervention developed by Ian Falloon for the treatment of schizophrenia, which has been adapted to major depression and to the Italian context. The experimental intervention will be administered individually to each recruited family and consists of six phases: 1) engagement of the family unit; 2) individual assessment; 3) family assessment; 4) informative sessions; 5) communication skills sessions; 6) problem-solving skills sessions.
Patients and their relatives will be provided with information on: 1) the clinical characteristics of MDD, including onset and course, symptoms, prognosis, risk and protective factors; 2) available pharmacological and non-pharmacological treatments of MDD, its indications, side effects and strategies to cope with them, treatment duration, risk factors for relapse, and effects related to abrupt cessation of the therapy; 3) early signs of crisis, with the identification of the user's specific signs, completion and use of an ad-hoc form, the usefulness of their recognition for the prevention of episodes. A specific informative session on suicide has been developed, which will be administered only if the patients had a previous suicide attempt or report suicidal ideation during the intervention.
Each meeting is ideally divided into three phases: a first phase dedicated to clarifications and questions regarding the topics previously discussed; a second phase focused on the main topic of the meeting (the so-called "teaching phase"); and a final phase, in which the salient aspects discussed during the meeting are summarized, and "homework" is assigned.
The control group will receive an informative intervention consisting of five sessions, administered every 7-10 days, with the following content: healthy lifestyle habits (diet and nutrition), stress management, regulation of circadian rhythms, and management of medications' side effects.
The interventions will be discontinued if: 1) patients or their relatives will be unable to attend more than five consecutive psychoeducational sessions; 2) patients will be hospitalized or had any affective relapse during the intervention; or 3) patients or relatives withdraw their consent.
In both groups, patients will continue to receive the treatment usually provided in their center.
Trainings for the conduction of the intervention and for the use of assessment tools will be provided by the coordinating center. Two researchers (at least one being a psychiatrist) for each center will participate in a four-day training. During the training, a manual to conduct the experimental intervention is provided to participants, and several role-plays are organized. At least one researcher per center, not involved in the administration of the interventions, will be trained in the use of assessment tools and inter-rater reliability measurement. The training will include the following phases: a) presentation of the assessment instruments; b) group reading; c) simulations of administration; d) video-recorded interviews.
Work hypotheses is that the PFI will be effective in reducing severity of depressive symptoms, relapses and hospitalizations, and an improvement in adherence to pharmacological treatments, quality of life a reduction in internalized stigma, and an improvement in coping strategies.
- Conditions
- Depressive Disorder, Major
- Being tested
- Psychoeducational Family Intervention, Informative intervention
- Keywords
- depression, caregiver, family, psychoeducation
- Medical subject headings
- Depressive Disorder, Major, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Psychoeducational Family InterventionOther
Supportive intervention administered to families with a member affected by MDD
Informative interventionOther
Informative intervention administered to families with a member affected by MDD
| Study group | Role | What they receive |
|---|---|---|
| Psychoeducational Family Intervention | Experimental | The experimental intervention will be administered individually to each recruited family. Sessions will take place three times a month for a period ranging from 4 to 6 months (about 18 sessions in total). The number of sessions, as well as the frequency, may vary depending on the patient's clinical situation. Sessions will have an average duration of 60-90 minutes. Receives: Other: Psychoeducational Family Intervention |
| Informative intervention | Active comparator | The informative intervention consists of five sessions, administered every 7-10 days. Receives: Other: Informative intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Severity of depressive symptoms
Hamilton Depression Rating Scale (HAM-D). The HAM-D includes 17 items. Of these, 8 items are scored from 0 (absent) to 4 (severe), while nine are scored from 0 to 2. The total score is performed by the sum of the items' scores, and ranges from 0 to 52 points.
Measured: At baseline, after 6-, 12- and 24 months
Psychosocial functioning
Personal and Social Performance Scale (PSP). A total score can be attributed to score the overall patient's functioning, ranging from 0 to 100, with higher scores indicating higher functioning. Ratings are based mainly on the assessment of patient's functioning in four main areas: (1) socially useful activities; (2) personal and social relationships; (3) self-care; and (4) disturbing and aggressive behaviors.
Measured: At baseline, after 6-, 12- and 24 months
Severity of anxiety symptoms
Hamilton Anxiety Rating Scale (HAM-A). It is a 14-items questionnaire developed to measure the severity of anxiety symptoms, both psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety). The score for each item ranges from 0 (not present) to 4 (extreme severity).
Measured: At baseline, after 6-, 12- and 24 months
Social contacts
Columbia Suicide Severity Rating Scale (C-SSRS). The clinician-administered version of the C-SSRS (screening version) will be administered. Individual's suicidal ideation is rated on a scale from 1 (wish to be dead) to 5 (active suicidal ideation with a specific plan and intent).
Social Network Questionnaire (SNQ).
Measured: At baseline, after 6-, 12- and 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2023
- Study start27 Sep 2023
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Depressive Disorder, MajorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 384 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Campania Luigi Vanvitelli
- Sponsor type
- University, hospital or other
- Collaborators
- Università degli Studi di Brescia, University of Bologna, University of Catanzaro, Università degli Studi 'G. d'Annunzio' Chieti e Pescara, University of Cagliari, University of Florence, Università degli Studi di Ferrara, University of Foggia, Universita degli Studi di Genova, University of Milan, University of Modena and Reggio Emilia, Università degli Studi del Piemonte Orientale Amedeo Avogadro, University of Parma, University Of Perugia, University of Pisa, Università Politecnica delle Marche, University of Roma La Sapienza, University of Rome Tor Vergata, Catholic University of the Sacred Heart, Università degli Studi di Sassari, University of Siena, Università degli studi di Trieste, Universita di Verona
- Responsible party
- Principal investigator, Mario Luciano, University of Campania Luigi Vanvitelli
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05988333
- Sponsor's protocol ID
- 0012764/2023
- Status last verified
- Apr 2024
- First submitted
- 4 Aug 2023
- Last updated
- 19 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy of Psychoeducational Family Intervention for Individuals With Major Depression: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05988333
- Acronym / sponsor ID
- 0012764/2023
- Conditions
- Depressive Disorder, Major
- Keywords
- depression, caregiver, family, psychoeducation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 384 participants (estimated)
- Lead sponsor
- University of Campania Luigi VanvitelliUniversity, hospital or other
- Collaborators
- Università degli Studi di Brescia, University of Bologna, University of Catanzaro, Università degli Studi 'G. d'Annunzio' Chieti e Pescara, University of Cagliari, University of Florence, Università degli Studi di Ferrara, University of Foggia, Universita degli Studi di Genova, University of Milan, University of Modena and Reggio Emilia, Università degli Studi del Piemonte Orientale Amedeo Avogadro, University of Parma, University Of Perugia, University of Pisa, Università Politecnica delle Marche, University of Roma La Sapienza, University of Rome Tor Vergata, Catholic University of the Sacred Heart, Università degli Studi di Sassari, University of Siena, Università degli studi di Trieste, Universita di Verona
- Study start
- 27 Sep 2023 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 14 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Major depressive disorder (MDD) is the most common mental disorder. It can be a huge burden not only for the person affected by it, but also for his/her whole family. The goal of this clinical trial is to test the efficacy of a family supportive intervention called psychoeducational family intervention (PFI) compared to a brief informative intervention in families with a member affected by MDD. Families will participate in one of the two interventions for a period of 6 months more or less, and they will be asked to answer some questionnaires about how much MDD impacts on their everyday life and the patient's symptoms, in order to understand whether a more structured intervention such as PFI can be useful for families in order to better deal with this complicated illness.
Detailed description
The present paper is a no-profit, not-funded, national, multicentric, randomized-controlled trial with blinded outcome assessments, carried out in 24 Italian University outpatient units and coordinated by the Department of Mental and Physical Health and Preventive Medicine of the University of Campania Luigi Vanvitelli. In each center, 8 patients (and their families) and 8 controls will be recruited, for a total of 192 families assigned to the experimental group and 192 to the control group (total sample size = 384 families). Families are assessed at the baseline and 6-, 12- and 24-months post-randomization.
The primary aim of this study is to assess the efficacy of PFI in a group of patients with a diagnosis of MDD in terms of: 1) reduction of depressive symptoms; 2) improvement of psychosocial functioning; 3) improvement of social network. Furthermore, the efficacy of PFI will be also evaluated in terms of: 1) reduction of relapses and hospitalization in the 18 months following the end of the intervention; 2) improvement of adherence to pharmacological treatments and of patients' quality of life; 3) reduction of self-stigma; 4) improvement of coping strategies, family burden, and expressed emotion of family members of patients with major depression; 5) improvement of quality of life of family members. Finally, our study will investigate whether the presence of specific temperamental profiles and childhood traumas may mediate the effectiveness of the psychoeducational intervention.
The experimental intervention consists of the psychoeducational family intervention developed by Ian Falloon for the treatment of schizophrenia, which has been adapted to major depression and to the Italian context. The experimental intervention will be administered individually to each recruited family and consists of six phases: 1) engagement of the family unit; 2) individual assessment; 3) family assessment; 4) informative sessions; 5) communication skills sessions; 6) problem-solving skills sessions.
Patients and their relatives will be provided with information on: 1) the clinical characteristics of MDD, including onset and course, symptoms, prognosis, risk and protective factors; 2) available pharmacological and non-pharmacological treatments of MDD, its indications, side effects and strategies to cope with them, treatment duration, risk factors for relapse, and effects related to abrupt cessation of the therapy; 3) early signs of crisis, with the identification of the user's specific signs, completion and use of an ad-hoc form, the usefulness of their recognition for the prevention of episodes. A specific informative session on suicide has been developed, which will be administered only if the patients had a previous suicide attempt or report suicidal ideation during the intervention.
Each meeting is ideally divided into three phases: a first phase dedicated to clarifications and questions regarding the topics previously discussed; a second phase focused on the main topic of the meeting (the so-called "teaching phase"); and a final phase, in which the salient aspects discussed during the meeting are summarized, and "homework" is assigned.
The control group will receive an informative intervention consisting of five sessions, administered every 7-10 days, with the following content: healthy lifestyle habits (diet and nutrition), stress management, regulation of circadian rhythms, and management of medications' side effects.
The interventions will be discontinued if: 1) patients or their relatives will be unable to attend more than five consecutive psychoeducational sessions; 2) patients will be hospitalized or had any affective relapse during the intervention; or 3) patients or relatives withdraw their consent.
In both groups, patients will continue to receive the treatment usually provided in their center.
Trainings for the conduction of the intervention and for the use of assessment tools will be provided by the coordinating center. Two researchers (at least one being a psychiatrist) for each center will participate in a four-day training. During the training, a manual to conduct the experimental intervention is provided to participants, and several role-plays are organized. At least one researcher per center, not involved in the administration of the interventions, will be trained in the use of assessment tools and inter-rater reliability measurement. The training will include the following phases: a) presentation of the assessment instruments; b) group reading; c) simulations of administration; d) video-recorded interviews.
Work hypotheses is that the PFI will be effective in reducing severity of depressive symptoms, relapses and hospitalizations, and an improvement in adherence to pharmacological treatments, quality of life a reduction in internalized stigma, and an improvement in coping strategies.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Psychoeducational Family Intervention | Experimental | Other: Psychoeducational Family InterventionThe experimental intervention will be administered individually to each recruited family. Sessions will take place three times a month for a period ranging from 4 to 6 months (about 18 sessions in total). The number of sessions, as well as the frequency, may vary depending on the patient's clinical situation. Sessions will have an average duration of 60-90 minutes. |
| Informative intervention | Active comparator | Other: Informative interventionThe informative intervention consists of five sessions, administered every 7-10 days. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- diagnosis of major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition;
- ability to provide informed consent;
- presence of at least one contact per month with the psychiatric clinic for at least six months prior to recruitment;
- cohabitation with at least one family member.
Key exclusion criteria (1 listed)
- moderate or severe cognitive deficits, physical illnesses preventing the participation to the sessions or if they were hospitalization in the two months prior the enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Psychoeducational Family InterventionSupportive intervention administered to families with a member affected by MDD | Other | Psychoeducational Family Intervention |
| Informative interventionInformative intervention administered to families with a member affected by MDD | Other | Informative intervention |
Primary outcome
Severity of depressive symptoms
Time frame: At baseline, after 6-, 12- and 24 months
Hamilton Depression Rating Scale (HAM-D). The HAM-D includes 17 items. Of these, 8 items are scored from 0 (absent) to 4 (severe), while nine are scored from 0 to 2. The total score is performed by the sum of the items' scores, and ranges from 0 to 52 points.
Psychosocial functioning
Time frame: At baseline, after 6-, 12- and 24 months
Personal and Social Performance Scale (PSP). A total score can be attributed to score the overall patient's functioning, ranging from 0 to 100, with higher scores indicating higher functioning. Ratings are based mainly on the assessment of patient's functioning in four main areas: (1) socially useful activities; (2) personal and social relationships; (3) self-care; and (4) disturbing and aggressive behaviors.
Severity of anxiety symptoms
Time frame: At baseline, after 6-, 12- and 24 months
Hamilton Anxiety Rating Scale (HAM-A). It is a 14-items questionnaire developed to measure the severity of anxiety symptoms, both psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety). The score for each item ranges from 0 (not present) to 4 (extreme severity).
Social contacts
Time frame: At baseline, after 6-, 12- and 24 months
Columbia Suicide Severity Rating Scale (C-SSRS). The clinician-administered version of the C-SSRS (screening version) will be administered. Individual's suicidal ideation is rated on a scale from 1 (wish to be dead) to 5 (active suicidal ideation with a specific plan and intent). Social Network Questionnaire (SNQ).
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Apr 2024.
- Individual participant dataSharing planned: No
Related trials for Depressive Disorder, Major
RecruitingPhase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Anxiety Disorders, Major Depressive Disorder
Active, not recruitingPhase 1
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Major Depressive Disorder
Active, not recruiting
Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
Depression, MDD
RecruitingPhase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
Not yet recruiting
Expressive Arts Therapy in Major Depression: An RCT
Depression - Major Depressive Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Psychoeducational Family Intervention and Informative intervention in people with Depressive Disorder, Major, run by University of Campania Luigi Vanvitelli at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mario Luciano, Doctor (+393490730150, mario.luciano@unicampania.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Severity of depressive symptoms (time frame: At baseline, after 6-, 12- and 24 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024.